NKF(603707)2025-01-24 09:20Financial Performance Forecast - The company expects a net profit attributable to shareholders of between 800 million and 1.05 billion yuan for the year 2024, indicating a turnaround from a loss in the previous year[4]. - The estimated net profit after deducting non-recurring gains and losses for 2024 is projected to be between 750 million and 1 billion yuan[4]. - The company plans to reverse inventory impairment provisions between 160 million and 240 million yuan in 2024, which is expected to increase net profit by approximately 136 million to 204 million yuan[8]. - The performance forecast is based on preliminary calculations and has not yet been audited by a registered accounting firm[9]. - The company emphasizes that the forecast data is subject to change and the final figures will be disclosed in the official 2024 annual report[10]. - There are currently no major uncertainties affecting the accuracy of the performance forecast[9]. Previous Financial Performance - In 2023, the company reported a net loss attributable to shareholders of approximately 189.45 million yuan[7]. - The company faced a significant inventory impairment of 1.24 billion yuan in 2023 due to downstream customer destocking in the heparin industry[8]. Raw Material Costs - The average procurement price of raw materials in 2024 is expected to decrease significantly compared to the previous year, leading to lower inventory costs[8]. Communication and Discrepancies - The company has communicated with its accounting firm regarding the performance forecast, and there are no significant discrepancies[4].